Building what’s next in MedTech

Eurofins Medical Device Services welcomes St. Louis Chemistry and Medical Device Testing Teams

The medical device industry is embracing an exciting new chapter of groundbreaking innovation and excellence, driven by the dynamic integration of top-tier expertise and expanded capabilities.

Eurofins Medical Device Services’ integration of the St. Louis Chemistry and Medical Device Testing business units from Eurofins’ EAG Laboratories—effective May 1—positions the organization to elevate the standards of medical device testing, development, and regulatory support, ushering in a new era of innovation and excellence.

This strategic move underscores a shared commitment to advancing MedTech and delivering exceptional solutions to clients.

Eurofins Medical Device Services, recognized as a leader in comprehensive medical device testing and regulatory services, welcomes the highly respected St. Louis teams into its network. The St. Louis facility, celebrated as a center of excellence for chemical characterization of medical devices, brings deep scientific rigor, technical depth, and a reputation for outstanding client service. In joining Eurofins Medical Device Services, the St. Louis teams will gain access to additional analytical platforms and cross-functional expertise, enhancing the ability to support product development, regulatory submissions, and ongoing quality programs. By integrating St. Louis capabilities, Eurofins strengthens its Biocompatibility Accelerator program, delivering faster, more predictable regulatory outcomes through end-to-end chemical characterization and biological safety alignment.

“This integration marks a pivotal step forward for our clients and our teams,” said Mike Bond, President, Medical Device Services. “By uniting Eurofins Medical Device Services with EAG’s St. Louis operations, we deliver broader expertise, faster innovation, and seamless support— empowering clients at every stage of the medical device lifecycle.”

The transition, effective as of May 1, 2026 will be smooth and uninterrupted, ensuring that day-to-day operations, scientific staff, and client commitments continue as usual. Importantly, all other EAG Laboratories business units and service lines remain unchanged and will continue operating as part of EAG.

St. Louis Medical Device Testing is widely regarded as “best in class” for ISO 10993-18 testing, with more than 700 studies completed over the last several years. To date, all submissions using St. Louis data have been accepted by the FDA. The lab also offers particulate analysis as well as in vitro sensitization and irritation studies.

Al Lee, Ph.D., Vice President of St. Louis Chemistry and Medical Device Testing, emphasized, “By joining Eurofins Medical Device Services, we will be able to further expand our technical capabilities, accelerate innovation, and continue delivering the high-quality, science-driven solutions our customers expect, without disruption to their projects or partnerships.”

The addition of the St. Louis teams strengthens Eurofins Medical Device Services’ position as a solutions partner as it remains steadfast in its mission: to build what’s next in medical technology, grounded in scientific excellence and client-centered innovation.

To learn more about the enhanced capabilities and the ways Eurofins Medical Device Services is building what’s next in MedTech, visit Eurofins.com/medical-device or contact your account manager for personalized guidance.

Global Expertise | Local Access | Proven Results